• the median time from remission to relapse was 13 months and 15 months, respectively (P = 0.023, log rank test). (nih.gov)
  • Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract characterized by episodes of relapse and remission. (frontiersin.org)
  • This meant it was highly unlikely Ben would go into remission, and if he did go into remission, he would very likely have a relapse. (justbetweenus.org)
  • Lower maternal educational level was associated with increased frequency of mucositis, as were induction chemotherapy and maintenance chemotherapy after relapse. (bvsalud.org)
  • The children with INS were divided into 3 groups of 20: first presentation, remission and relapse. (who.int)
  • The first-line treatment typically includes chemotherapy combined with immunotherapy, which is a combination of medications that destroy the cancer cells. (rarediseases.org)
  • In a large international study of people with this form of AML who can't have intensive chemotherapy , combining a drug called ivosidenib (Tibsovo) with the chemotherapy drug azacitidine was substantially more effective at producing remissions than azacitidine alone . (cancer.gov)
  • If possible, people newly diagnosed with AML receive an intensive regimen of multiple chemotherapy drugs, with the goal of pushing the disease into a complete remission -that is, eliminating leukemia cells in the bone marrow . (cancer.gov)
  • In the United States, before the combination of azacitidine and venetoclax was approved, people who were ineligible for induction chemotherapy-that is, they were too sick or past the age considered safe to receive it-often received azacitidine alone, with the goal of reducing the symptoms of leukemia and extending how long they lived. (cancer.gov)
  • Overall, COP chemotherapy causes complete remission in about 70% of dogs with lymphoma for a median of 130 days. (vin.com)
  • Chemotherapy for AML is broken down into three phases: induction phase, consolidation (or intensification), and maintenance phase. (oncolink.org)
  • Most children with T-cell acute lymphoblastic leukemia (ALL) can be treated with standard chemotherapy regimens, but patients with induction failure or elevated minimal residual disease after consolidation generally receive allogeneic stem-cell transplantation. (ajmc.com)
  • When chemotherapy is used at the beginning of your cancer treatment and before starting radiation therapy , it's referred to as induction chemotherapy. (healthline.com)
  • The goal of induction chemotherapy is to shrink tumors before beginning radiation therapy. (healthline.com)
  • Keep reading as we take a look at when induction chemotherapy may be used and how it compares to consolidation therapy and other types of chemotherapy. (healthline.com)
  • What is induction chemotherapy? (healthline.com)
  • Induction chemotherapy is the type used before radiation therapy. (healthline.com)
  • The term induction chemotherapy is often used interchangeably with the term neoadjuvant chemotherapy, even among cancer researchers. (healthline.com)
  • However, induction chemotherapy should be used when chemotherapy occurs before radiation therapy. (healthline.com)
  • The goal of induction chemotherapy is to reduce tumor size to make it easier for radiation therapy to get rid of cancer cells and to reduce the chances of cancer spreading to distant parts of your body. (healthline.com)
  • How does induction chemotherapy compare to consolidation chemotherapy? (healthline.com)
  • Induction chemotherapy is used as a first-line treatment for cancer to prepare you for radiation therapy. (healthline.com)
  • The combination of chemotherapy drugs administered is often similar as during induction therapy. (healthline.com)
  • The length of induction chemotherapy can vary based on the type and extent of your cancer. (healthline.com)
  • Side effects are similar between induction and consolidation chemotherapy. (healthline.com)
  • Induction chemotherapy may be used to treat people with esophageal cancer that has spread to surrounding tissues. (healthline.com)
  • Clinical trials have found that induction chemotherapy seems to be at least equally as effective as chemotherapy and radiation therapy together for treating head and neck cancers. (healthline.com)
  • A 2016 study found evidence that patients with stage 2 or stage 3 non-small cell lung cancer may benefit from induction chemotherapy before concurrent chemotherapy and radiation therapy. (healthline.com)
  • Neoadjuvant is sometimes also referred to as induction chemotherapy. (healthline.com)
  • Acute leukemias are often treated with induction therapy and consolidation chemotherapy once the cancer is in remission. (healthline.com)
  • What are the pros and cons of induction chemotherapy? (healthline.com)
  • Oral lesions were associated with the induction phase of chemotherapy. (bvsalud.org)
  • Most patients up to the age of approximately 75 years should be considered for intensive combination chemotherapy with the aim to induce complete remission. (cancercentrum.se)
  • Many affected individuals have widespread disease at diagnosis, with involved regions often including multiple lymph nodes, the spleen, and, potentially, the bone marrow, the liver, and/or regions of the digestive (gastrointestinal) tract. (rarediseases.org)
  • Lymphatic tissues also include the thymus, a relatively small organ behind the breastbone that is thought to play an important role in the immune system until puberty, as well as the bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
  • When leukemic blasts replace the bone marrow, patients present with signs of bone marrow failure, including anemia, thrombocytopenia, and neutropenia. (medscape.com)
  • Remission is when there are less than 5% blast cells in the bone marrow. (oncolink.org)
  • On day 27, the patient's bone marrow was hypocellular and in morphologic remission with undetectable minimal residual disease and she was discharged 52 days after stem-cell transplantation. (ajmc.com)
  • Bone marrow analysis at 9 months post-transplant showed normal morphologic characteristics and confirmed ongoing molecular remission. (ajmc.com)
  • Induction: Administer 0.15 mg/kg/day intravenously daily in combination with tretinoin until bone marrow remission. (centerwatch.com)
  • Induction: Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. (centerwatch.com)
  • Budesonide rectal foam is used to help get mild to moderate active ulcerative colitis that extends from the rectum to the sigmoid colon under control (induce remission). (mayoclinic.org)
  • The company achieved both co-primary endpoints of endoscopic response and clinical remission, as well as key secondary endpoints of rapid clinical response and corticosteroid-free clinical remission, with statistical significance. (yahoo.com)
  • Corticosteroid-free remission and corticosteroid-free response were experienced by 30% and 54%, respectively, of the entire cohort, and were similar between the two groups. (medscape.com)
  • To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). (bvsalud.org)
  • Using multivariable logistic regression modeling, we compared the primary outcome of clinical remission, and secondary outcomes of clinical response and mucosal healing, according to clinical trial definitions, between male and female patients with UC at week 6 (golimumab) or week 8 (infliximab) of induction therapy. (ecco-ibd.eu)
  • Based on this analysis of pooled data from RCTs, we demonstrate that clinical remission, response and mucosal healing with TNFi induction therapies are less likely in male patients compared to female patients with UC. (ecco-ibd.eu)
  • At week 8, patients (n=961) were evaluated for clinical remission, endoscopic healing, clinical response, change from baseline in the IBDQ score, and mucosal healing (an endpoint that includes both endoscopic healing and histologic healing). (jnj.com)
  • Additional utilities of biological therapies have included demonstrable mucosal healing, improvement in quality of life, reduction in surgeries and hospitalizations, and the treatment of extraintestinal manifestations of IBD including central and peripheral arthritis and pyoderma gangrenosum. (nih.gov)
  • During the ADVANCE and MOTIVATE induction studies, a significantly greater proportion of patients treated with SKYRIZI 600 mg IV achieved mucosal healing and endoscopic remission. (lifesciencesbc.ca)
  • Mucosal healing and endoscopic remission were observed during the FORTIFY maintenance trial in patients treated with SKYRIZI 360 mg SC. (lifesciencesbc.ca)
  • Complete remission was achieved in 84% of dogs for a median of about 9 months. (vin.com)
  • At a median follow-up time of 16 months, 68% of patients who had achieved complete remission were still alive and 58% were disease free. (centerwatch.com)
  • In the entire cohort, 25 patients (75.7%) achieved complete remission (CR, CRu-unconfirmed), with mean progression-free survival (PFS) 32 ± 6.9 months and median overall survival (OS) 59.6 ± 12.4 months. (ima.org.il)
  • Major secondary endpoints including the proportion of patients in clinical response, endoscopic healing, as well as improvement in health-related quality of life, were also significantly higher at week 8 among patients receiving STELARA compared with patients receiving placebo. (jnj.com)
  • In the ADVANCE and MOTIVATE induction trials, a significantly greater proportion of patients treated with SKYRIZI 600 mg IV achieved the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response. (lifesciencesbc.ca)
  • In the FORTIFY maintenance trial, a significantly greater proportion of patients treated with SKYRIZI 360 mg SC achieved the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response. (lifesciencesbc.ca)
  • Additionally, during the induction studies, 24% and 19% of patients treated with SKYRIZI 600 mg IV achieved endoscopic remission at week 12, respectively, compared to 9% and 4% of patients receiving placebo. (lifesciencesbc.ca)
  • The endoscopic response was observed in 34% and 46% of patients treated with a 45 mg dose of Rinvoq, in the two induction studies at week 12, respectively, compared with 3% and 13% of patients receiving placebo. (yahoo.com)
  • The study's primary endpoint was remission at week 30. (eurekalert.org)
  • The DMC advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1. (myhighplains.com)
  • As part of the analysis, the DMC performed a safety review and a futility assessment based on the primary endpoint clinical remission at week 6. (myhighplains.com)
  • Cytoxan ( cyclophosphamide ) and corticosteroids are frequently used as part of induction therapy nowadays. (medicinenet.com)
  • Randomized trial of cyclophosphamide versus methotrexate for induc tion of remission in early systemic antineutrophil cytoplasmic antibody the management of granulomatosis with polyangiitis continues associated vasculitis. (ehd.org)
  • [ 3 ] Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. (medscape.com)
  • Since introduced by Fauci et al in the 1970s, oral cyclophosphamide in combination with high-dose glucocorticoids (ie, prednisone 1mg/kg/day) has been the criterion standard for induction of remission in AAV. (medscape.com)
  • Eventually, intravenous cyclophosphamide was investigated as an alternative to oral cyclophosphamide in an effort to decrease treatment-associated toxicities, and, while the emphasis has been placed on optimizing treatment by minimizing exposure to cyclophosphamide and seeking alternative comparable therapies, the combination of cyclophosphamide (intravenous or oral) and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. (medscape.com)
  • In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab (a monoclonal antibody that targets B cells), in combination with glucocorticoids, as an alternative to cyclophosphamide for induction of remission in AAV (GPA and microscopic polyangiitis). (medscape.com)
  • This approach is meant to cause complete or partial disappearance of the cancer (remission). (rarediseases.org)
  • In both cases-incomplete response or complete remission—if the disease eventually relapses, clinicians will move to salvage therapy. (pharmacytimes.com)
  • The goals of therapy for AML include complete remission, restoration of normal hematopoietic functions, and no evidence of measurable residual disease. (pharmacytimes.com)
  • He also indicated that induction failure is failure to attain a complete response following at least 2 courses of induction. (pharmacytimes.com)
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • Many, including complete strangers, joined our journey of faith through a Facebook page, "The Ben Ripple. (justbetweenus.org)
  • To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. (centerwatch.com)
  • The drug was shown to be effective with 70% of the patients achieving complete remission. (centerwatch.com)
  • 22 of these (91%) entered a complete remission (CR). (lu.se)
  • Interim results, which were presented during the 2020 European Hematology Association Congress and analyzed after 6 cycles of induction therapy, demonstrated an overall response rate (ORR) of 100%, a very good partial response rate (VGPR) or better of 90%, and a complete response (CR)/stringent CR (sCR) rate of 46% among 50 evaluable patients. (onclive.com)
  • Benefits of vaccination include partial or complete protection against the consequences of infection for the vaccinated person, as well as overall benefits to society as a whole. (cdc.gov)
  • The results showed that all 50 patients were evaluable for response and all achieved at least a partial remission. (onclive.com)
  • Classic microscopic features of GPA include inflammation of blood vessels associated with poorly formed granulomas, necrosis, and many giant cells. (wikipedia.org)
  • Compared to female patients, male patients were significantly less likely to achieve clinical remission in both treatment and placebo arms (aOR 0.55, 95% CI 0.31, 0.97 and 0.34, 95% CI 0.15, 0.82, respectively, Figure). (ecco-ibd.eu)
  • Clinical remission is also less likely in male patients on placebo. (ecco-ibd.eu)
  • Results from the induction phase of the Phase 3 UNIFI study show that treatment with a single IV dose of STELARA induced clinical remission in a significantly greater proportion of UC patients at week 8, compared with placebo, at both doses studied. (jnj.com)
  • 1 The three Phase 3 studies are multicenter, randomized, double-blind, placebo-controlled studies and include assessments of efficacy, safety and tolerability of SKYRIZI. (lifesciencesbc.ca)
  • In ADVANCE and MOTIVATE, 43% and 35% of patients treated with SKYRIZI 600 mg IV achieved clinical remission at week 12, respectively, compared to 22% and 19% of patients receiving placebo. (lifesciencesbc.ca)
  • In FORTIFY, 52% of patients treated with SKYRIZI 360 mg SC achieved clinical remission at week 52 compared to 40% of patients receiving placebo. (lifesciencesbc.ca)
  • In the induction studies, 45 mg dose of Rinvoq was used and dose strengths of 15 mg and 30 mg of Rinvoq were used in the maintenance study, compared with placebo. (yahoo.com)
  • A clinical remission was achieved in 36% and 46% of patients treated with Rinvoq 45 mg, in the two induction studies at 12 weeks, respectively, compared with 18% and 23% of patients receiving placebo. (yahoo.com)
  • Moreover, 42% and 55% of patients treated with Rinvoq 15 mg and 30 mg achieved clinical remission at 52 weeks in the maintenance study, compared with 14% of patients receiving placebo. (yahoo.com)
  • there is no role for radiation or surgical treatment in the induction phase. (medscape.com)
  • All patients in the LUCENT program had moderately to severely active UC and had experienced treatment failure or could not tolerate past treatments, including biologic therapies. (medscape.com)
  • The MTX regimen used in the present study was less effective for induction of remission in patients with extensive disease and pulmonary involvement and was associated with more relapses than the CYC regimen after termination of treatment. (nih.gov)
  • These finding may lead to further research on sex-based differences in treatment outcomes, including mechanistic studies. (ecco-ibd.eu)
  • Prognostic factors include stage and substage of disease, histologic type, immunophenotype (B-cell versus T-cell), presence of hypercalcemia, response to therapy, pre-treatment steroid therapy, and possibly gender. (vin.com)
  • Most veterinary oncologists agree that unless palliation rather than extended remission is the goal of therapy, single agent treatment of lymphoma should be avoided. (vin.com)
  • These include your age, your AML subtype, if you have had treatment for other cancers in the past, your overall health, and testing results. (oncolink.org)
  • after a remission, you will enter this second phase of treatment. (oncolink.org)
  • A typical course of treatment for a patient with AML includes induction, followed by re-induction if the patient has an incomplete response. (pharmacytimes.com)
  • We thanked God Ben went into remission one week shy of the completion of the induction phase of treatment. (justbetweenus.org)
  • ATLANTA -- New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care. (eurekalert.org)
  • According to their results, therapeutic drug monitoring was not superior to standard treatment for achieving disease remission at 30 weeks in people with a range of rheumatic diseases. (eurekalert.org)
  • In the study's therapeutic drug monitoring arm, 100 or 53% of patients achieved remission, while 106 or 54% of the patients in the standard treatment group also achieved remission. (eurekalert.org)
  • Our study does not support therapeutic drug monitoring be applied as a general treatment strategy during induction of infliximab. (eurekalert.org)
  • PHILADELPHIA, PENNSYLVANIA, October 9, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data showing treatment with a single intravenous (IV) dose of STELARA ® (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously experienced an inadequate response or were intolerant to conventional or biologic therapies. (jnj.com)
  • Ulcerative colitis is a complex immune disease, and more than half of UC patients have not experienced remission with currently available conventional or biologic treatment options," said lead investigator Bruce E. Sands, MD, Dr. Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai. (jnj.com)
  • The significant rates of remission observed through the 8-week induction, coupled with a safety profile that is well-documented through years of research and use in other immune diseases, demonstrate the potential for ustekinumab as an effective treatment for UC. (jnj.com)
  • Since then, the indications for anti-tumor necrosis factor-α (anti-TNFα) therapy have increased to include induction and maintenance of clinical responses and remissions for luminal and fistulizing CD, the treatment of children with CD, and the treatment of adults with ulcerative colitis. (nih.gov)
  • Total remission was reached, on average, within two months after treatment with Trisenox began. (centerwatch.com)
  • Additionally, treatment recommendations are different for induction of remission and maintenance of remission. (medscape.com)
  • NORTH CHICAGO, IL - AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI ® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. (lifesciencesbc.ca)
  • 33 patients received a HDMTX backbone induction therapy, 21 (58.3%) received consolidation treatment in addition. (ima.org.il)
  • An induction therapy is the first treatment for a disease. (healthline.com)
  • Treatment typically includes immunosuppression with corticosteroids and cytotoxic drugs. (msdmanuals.com)
  • The interim analysis included data on the first 50 patients that were enrolled in the trial [and responded] during induction treatment with [the quadruplet regimen]. (onclive.com)
  • This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. (bvsalud.org)
  • The Swedish AML group (for participants, see www.svenskaamlgruppen.se) has published national care programs since 2005, including basic background and recommendations for diagnosis, treatment and supportive care. (cancercentrum.se)
  • The maximum duration of treatment will be 36 months, including the Induction, Maintenance, and OLE Periods. (who.int)
  • We analyzed data from three etanercept down-titration studies in patients with RA to determine what extent of remission provides the greatest predictability of maintaining remission following dose reduction or discontinuation. (whiterose.ac.uk)
  • Then, we evaluated whether they maintained remission or LDA following etanercept dose reduction or withdrawal. (whiterose.ac.uk)
  • RESULTS:Patients achieving sustained and/or deep remission were more likely than patients achieving remission or LDA to maintain remission/LDA after etanercept dose reduction or withdrawal. (whiterose.ac.uk)
  • CONCLUSIONS: These results suggest that patients achieving disease control according to a stringent definition, such as sustained ACR/EULAR Boolean or CDAI remission, or a new definition of sustained deep remission by DAS28, have a higher probability of remaining in remission or LDA following etanercept dose reduction or withdrawal. (whiterose.ac.uk)
  • InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE. (myhighplains.com)
  • The patient should be observed closely for signs that the dose may need to be altered, such as changes in clinical status resulting from disease remissions or exacerbations. (who.int)
  • Induction therapies are also called first-line therapies or primary therapies. (healthline.com)
  • The trials showed that mirikizumab achieved primary and secondary endpoints, including sustained clinical remission and significantly improved bowel urgency. (medscape.com)
  • The presence of such secondary aberrations did not correlate with any morphological or clinical characteristics, including survival. (lu.se)
  • At 6 months, the remission rate in patients treated with MTX (89.8%) was not inferior to that in patients treated with CYC (93.5%) (P = 0.041). (nih.gov)
  • Typical signs and symptoms include nosebleeds, stuffy nose and crustiness of nasal secretions, and inflammation of the uveal layer of the eye. (wikipedia.org)
  • Typical signs and symptoms of nose or sinus involvement include crusting around the nose, stuffiness, nosebleeds, runny nose, and saddle-nose deformity due to a hole in the septum of the nose. (wikipedia.org)
  • The symptoms of this disease include persistent diarrhea and abdominal pain. (yahoo.com)
  • The researchers included 198 patients in the therapeutic drug monitoring arm and 200 patients were included in the control group. (eurekalert.org)
  • Methods Demographic, clinical and pharmacological variables, including tacrolimus whole blood concentrations obtained from therapeutic drug monitoring and data from dense-sampling pharmacokinetic profiles, were recorded in 26 paediatric patients with biliary atresia who underwent liver transplantation between 2016 and 2021. (unav.edu)
  • Adverse events (mean 0.87 episodes/patient) included leukopenia, which was less frequent in the MTX versus the CYC group (P = 0.012), and liver dysfunction, which was more frequent in the MTX group (P = 0.036). (nih.gov)
  • If the patient responds completely and goes into remission, he or she progresses to consolidation with postremission therapy or transplant. (pharmacytimes.com)
  • Today's launch of Adalimumab, in partnership with Fujifilm Kyowa Kirin Biologics, is yet another testament to the power of Viatris' unique Global Healthcare Gateway ® which helps partners like Fujifilm Kyowa Kirin Biologics with strong scientific expertise to further expand patient access to more affordable medicines in more markets around the world, including here in Japan, by leveraging Viatris' unmatched global infrastructure and regulatory expertise. (fujifilm.com)
  • The pre-specified and independent analysis included the first 133 patients (i.e., approximately 30% of the total 440 patient enrollment in Induction Study 1) who had completed the 6-week induction study. (myhighplains.com)
  • Normally, high-risk patients are included in all-comer trials and represent 15% to 20% of the total patient population, upon which we base our subgroup analyses," said Weisel. (onclive.com)
  • Week 14 clinical remission was attained in 10/25 (40%) of VDZ-aTNF patients versus 23/50 (46%) of VDZ patients (OR = 0.8, 95% CI 0.3-2.1, P = 0.6) and clinical response in 19/25 (76%) versus 39/50 (78%) respectively (OR = 0.9, 95% CI 0.3-2.7, P = 0.8). (medscape.com)
  • Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. (nih.gov)
  • But these drug combinations, called induction therapy , are incredibly taxing on the body. (cancer.gov)
  • For these patients, "and for people with many other coexisting medical problems, the ability to survive induction therapy is low. (cancer.gov)
  • Even in very healthy people over the age of 75, AML may not respond to induction therapy, she added. (cancer.gov)
  • We conducted a pooled analysis of individual-level data from randomized clinical trials (RCTs) on induction therapy with infliximab and golimumab, accessed through the Yale University Open Data Access platform. (ecco-ibd.eu)
  • The goal of this therapy is to put you in remission. (oncolink.org)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • To use data from clinical genomic sequencing of diagnosis, germline/remission and MRD samples to guide therapy, including incorporation of targeted agents and institution of genetic counseling and cancer surveillance. (centerwatch.com)
  • What types of cancers is induction therapy used for? (healthline.com)
  • Eligible patients received quadruplet therapy that consisted of an anti-CD38 monoclonal antibody, carfilzomib which is a next-generation PI, lenalidomide, and dexamethasone to induce MRD-negative remissions. (onclive.com)
  • Urgent administration of ATRA should be initiated with aggressive supportive measures including blood product support with platelets and cryoprecipitate while the genetic diagnosis is rapidly established. (nature.com)
  • The FDA approval was based on results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance trials, published last July in The New England Journal of Medicine . (medscape.com)
  • We included 1639 patients (696, 42.5% were women, Table) from two trials using infliximab (ACT-1 and 2) and one trial using golimumab (PURSUIT). (ecco-ibd.eu)
  • METHODS: Patients with moderate to severe RA from the PRESERVE, PRIZE, and Treat-to-Target (T2T) randomized controlled trials were included. (whiterose.ac.uk)
  • METHODS: We included 15 trials of BMI (N = 5903;59% women, 72% White) from Project INTEGRATE. (bvsalud.org)
  • We determined the proportion of patients achieving remission with etanercept at the last time point in the induction period, and sustained remission (last two time points), according to the Disease Activity Score 28-joints (DAS28), the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean criteria, and the clinical disease activity index (CDAI). (whiterose.ac.uk)
  • We also calculated the proportion achieving DAS28 deep remission (DAS28 ≤ 1.98), sustained deep remission (last two time points), and low disease activity (LDA), and LDA according to the CDAI. (whiterose.ac.uk)
  • The proportion of participants achieving PRO2 remission at week 12. (who.int)
  • These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. (bvsalud.org)
  • RESULTS: Nine RCTs with 5,295 children in total were included. (bvsalud.org)
  • The study included 411 patients from 21 medical centers between January 2017 and December 2018: 80 with rheumatoid arthritis, 42 with psoriatic arthritis, 117 with spondyloarthritis, 80 with ulcerative colitis, 57 with Crohn's, and 22 with psoriasis. (eurekalert.org)
  • The EC approval for SKYRIZI in Crohn's disease is supported by results from the global Phase 3 program, which included three studies: ADVANCE induction, MOTIVATE induction and FORTIFY maintenance. (lifesciencesbc.ca)
  • To learn more, researchers in Norway launched the first open-label, multi-center, randomized, controlled trial to assess its effectiveness in achieving remission in patients with several inflammatory diseases. (eurekalert.org)
  • Local (intra-articular or intralesional) injection of [CV004 trade name] may be given as part of the short-term management of inflammatory joint and tendon disorders, and localised inflammatory and hypertrophic skin lesions including those of lichen simplex, lichen planus, granuloma annulare, discoid lupus erythematosus, and keloids. (who.int)
  • In the MTX group, remission was delayed among patients with more extensive disease (P = 0.04) or pulmonary involvement (P = 0.03). (nih.gov)
  • Patients with active disease also had an increased prevalence of depression and anxiety compared with those in remission ( 3 , 6 ). (frontiersin.org)
  • Mutations in this particular gene are associated with a shorter duration of remission, decreased disease-free survival, and poor outcomes. (pharmacytimes.com)
  • Investigators also assessed the presence of minimal residual disease (MRD) in 33 patients in Arm A during induction and found that the majority, or 61%, were MRD negative. (onclive.com)
  • Societal benefits include creation and maintenance of herd immunity against communicable diseases, prevention of disease outbreaks, and reduction in health-care--related costs. (cdc.gov)
  • Although some sample sizes were small, the PRIZE and T2T studies also demonstrated response trends according to ACR/EULAR Boolean and CDAI remission criteria, and T2T demonstrated response trends according to DAS28. (whiterose.ac.uk)
  • The stimulation of certain bioprotective functions, including antioxidative capacity, DNA repair functions, apoptosis, and immune functions are thought to underly the adaptive response. (go.jp)
  • The adaptive response is effective for chromosome induction, acute death, and tumorigenesis induced by high doses of radiation. (go.jp)
  • Phenotypic and functional alterations in lupus T cells including expansion of the Th17 population, perturbations of the physiology of T-cell receptors (TCRs) and postreceptor downstream signalling, oxidative stress, and epigenetic changes result in exaggeration of TCR response to stimuli and the propensity of lupus T cells to get activated [ 6 ]. (hindawi.com)
  • Early studies with induction including 6-mercatopurine (6-MP) alone or in combination with steroids, methyl-glyoxal guanyl hydrazine and/or methotrexate led to poor results. (nature.com)
  • The goal of consolidation is to keep you in remission. (oncolink.org)
  • The primary end point was the remission rate at 6 months (noninferiority testing). (nih.gov)
  • Mutations in this gene cause various glaucoma phenotypes including primary congenital glaucoma, autosomal dominant iridogoniodysgenesis anomaly, and Axenfeld-Rieger anomaly. (cancerindex.org)
  • It is an individualized strategy that includes regular assessments of a patient's serum drug levels. (eurekalert.org)
  • Patients with acute promyelocytic leukemia (APL) are treated according to a separate protocol (included in the care program) based on all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). (cancercentrum.se)
  • Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. (cdc.gov)
  • The FDA approval was based on positive data from two induction studies, U-EXCEED and U-EXCEL and one maintenance study, U-ENDURE. (yahoo.com)
  • But by the six month marker, Ben had spent half his days in the hospital dealing with one complication after another, including three weeks over Christmas and New Year's that he didn't even remember. (justbetweenus.org)
  • Unfortunately, this round of chemo was unsuccessful in achieving remission, but with this news came our biggest reality check yet ─ Ben had days, maybe weeks, to live. (justbetweenus.org)
  • Conclusions Vedolizumab/anti-TNF co-exposure did not generate new safety signals during 14-weeks induction, nor did it reduce efficacy or alter vedolizumab pharmacokinetics. (medscape.com)
  • Results Seventy-five patients were included (25 VDZ-aTNF, 50 VDZ). (medscape.com)